|
Jul 1
|
Biogen Begins Phase III Felzartamab Study for Third Kidney Disease
|
|
Jul 1
|
3 Reasons BIIB is Risky and 1 Stock to Buy Instead
|
|
Jun 30
|
AbbVie to buy Capstan for up to $2.1 billion in immunology push
|
|
Jun 30
|
RBC says Lilly could blaze trail and Biogen could pull ahead in Alzheimer’s market
|
|
Jun 30
|
Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy
|
|
Jun 28
|
Biogen highlights ‘promising’ results for higher-dose nusinersen in SMA trials
|
|
Jun 28
|
Biogen Advances Once-Yearly SMA Therapy Salanersen to Phase 3 After Positive Phase 1 Results
|
|
Jun 27
|
New Data for Nusinersen Underscore Biogen’s Commitment to Advancing Clinical Research to Improve Outcomes in SMA
|
|
Jun 26
|
5 Revealing Analyst Questions From Biogen’s Q1 Earnings Call
|
|
Jun 16
|
Supernus makes depression drug play with $795m Sage buyout
|
|
Jun 16
|
Supernus Pharmaceuticals Snaps Up Beleaguered Sage Therapeutics
|
|
Jun 16
|
Sage, following Setbacks, to sell to Supernus for $561M
|
|
Jun 15
|
Biogen, UCB Present Positive Phase 3 Results for Lupus Drug Candidate at EULAR 2025
|
|
Jun 13
|
1 Profitable Stock with Exciting Potential and 2 to Avoid
|
|
Jun 12
|
Dapirolizumab Pegol Phase 3 Data in SLE Presented at the Annual European Congress of Rheumatology (EULAR) Show Improvement in Fatigue and Reduction in Disease Activity
|
|
May 27
|
Biogen (NasdaqGS:BIIB) Partners With City Therapeutics in US$1 Billion RNAi Therapy Deal
|
|
May 27
|
Biogen strikes RNAi deal with City; Aurion withdraws IPO
|
|
May 27
|
Biogen and City Therapeutics Announce Strategic Research Collaboration to Develop Select Novel RNAi-based Therapies
|
|
Apr 16
|
Biogen & Partner Eisai Get EU Nod for Alzheimer's Drug Leqembi
|
|
Apr 16
|
EC authorises Eisai and Biogen’s lecanemab for Alzheimer’s
|